Non-invasive monitoring of smoldering multiple myeloma: The iMMunocell study
What is the purpose of this study?
Determine the level of concordance between tumor/immune landscape in bone marrow (BM) vs peripheral blood (PB) of SMM patients. Evaluate immune profiles together with circulating tumor cell (CTC) numbers and genetic alterations every 6 months in PB, as minimally-invasive methods for identification of SMM patients at risk of developing active MM.
In this video:
Dr. Bruno Paiva discusses the prospect of a minimally invasive technique for continual monitoring smoldering multiple myeloma (SMM). Preliminary results of the iMMunocell study show circulating tumor cells (CTC) taken from the peripheral blood, as opposed to invasive bone marrow aspirates can provide clinical benefit, where CTC counts are significantly correlated to progressive disease.
Results show a significant correlation between CTC counts and stable vs progressive disease, and suggest that CTC kinetics could be complementary to the 2/20/20 criteria for real-time identification of individual SMM patients at risk of developing active MM
In conclusion, this non-invasive technique could potentially complement the 20/20/20 criteria for real-time monitoring of key immune cell types associated with malignant transformation and in turn, can identify patients at risk of disease progression into active multiple myeloma (MM).
ASH 2020: Abstract 57
Bruno Paiva, PhD
Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain, is responsible for the Flow Cytometry Laboratory and is the Co-Coordinator of the Center for Applied Medical Research (CIMA) LAB diagnostics. He joined CIMA in 2013 and his research interests lie in multiparameter flow cytometry for malignant hemopathies, such as multiple myeloma, Waldenstrom’s macroglobulinemia and primary systemic amyloidosis.